Beijing Jingyu Furui Technology Group Co., Ltd. specializes in the research, development, and production of pharmaceutical and chemical products, and has been honored with the National Science and Technology Progress Second Prize, recognized as a National High-Tech Enterprise, and designated as a "Specialized, Refined, Unique, and New" enterprise. The group's development strategy spans from specialty active pharmaceutical ingredients (APIs) to complex generic drugs and innovative formulations, aiming to become a leading pharmaceutical industry group in China. The company is in a phase of rapid growth, currently operating two production bases with one additional industrial base under construction. By 2023, it is projected to achieve a small-molecule chemical production capacity of nearly 250,000 liters. Additionally, the group has a research laboratory in Beijing focused on small-molecule compound CDMO (Contract Development and Manufacturing Organization), equipped with efficient capabilities from R&D to industrialization. In 2022, Jingyu Group successfully invested in the renowned German innovative pharmaceutical company Dermaliq. The two parties will collaborate on the development of multiple transdermal innovative drugs and formulations based on the innovative excipient "semi-fluorinated alkane," filling a gap in this field in China. The group's main subsidiaries include: Baiyin Jingyu New Pharmaceutical Co., Ltd., Baiyin Jingyu Furui Materials Co., Ltd., Beijing Jingyu Synthesis Technology Co., Ltd., and Gansu Jingyu Ruixiang Pharmaceutical Co., Ltd.

Jingyu New Pharmaceutical is located in the Baiyin Liuchuan Industrial Park in Jingyuan County, Baiyin City, Gansu Province, 130 kilometers from Lanzhou Zhongchuan Airport. It is a national high-tech enterprise specializing in the research, development, production, and sales of APIs and pharmaceutical intermediates. The factory covers an area of 80,000 square meters and is equipped with over a hundred reaction vessels capable of conducting various chemical reactions, including hydrogenation, bromination, reduction, diazotization, oxidation, alkylation, Grignard reactions, and low-temperature reactions. Jingyu New Pharmaceutical has a comprehensive quality system, having passed ISO9001 quality system certification. In 2020, it underwent an on-site compliance inspection for the "Drug Manufacturing License" by the Gansu Provincial Medical Products Administration and obtained the license in 2021. The company operates in strict accordance with GMP requirements and has undergone over ten audits annually by domestic and international clients since its establishment. Leveraging卓越的技术研发转化能力, extensive production experience, and a robust quality assurance system, the company has established long-term, deep, and stable partnerships with numerous renowned pharmaceutical companies both domestically and internationally. It continues to expand its sales network and promptly respond to customer needs, striving to become a globally competitive specialty pharmaceutical enterprise.

Jingyu Furui Materials was established in 2020 to expand its fine chemical business in areas such as basic chemicals, pesticides, and materials. The company operates through technical cooperation and contract manufacturing, focusing on revolutionary green chemical processes to achieve large-scale and continuous production of bulk chemicals. Currently, the company has built a specialized bromination production line with extensive experience in using bromine. Jingyu Synthesis Technology was established in 2020, primarily engaged in CDMO business for small-molecule compounds, offering custom synthesis services from gram to hundred-kilogram scales. The key personnel have years of experience working at well-known CXO companies, with extensive expertise in target compound customization, process optimization, and the development of novel synthetic routes. Jingyu Synthesis Technology synergizes with Jingyu New Pharmaceutical to provide customers with product development and GMP production services across all stages, from preclinical to clinical phases I-III and commercialization.

Jingyu Ruixiang Pharmaceutical was established in 2022 as a high-tech pharmaceutical enterprise primarily engaged in the production of high-value-added specialty APIs. The company plans to occupy a total area of approximately 40,000 square meters and is expected to be completed and operational by 2023.